BioCryst Pharmaceuticals Inc

BCRX remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price below the 9/21 EMAs and 50 DMA. The medium-term bias stays bearish, reinforced by the active Bearish Pivot Point and failed rebound attempts. Short-term timing shows rejection at EMA resistance and no sign of stabilization—favor selling into rallies at the 9/21 EMA zone. The speculative strategy supports continued participation in downtrend extensions.

• ↑Q1 2026 Orladeo net sales hit $148.3M, up 21% YoY
• ↑84% paid patient rate accelerates revenue conversion
• ↓Negative profitability metrics and earnings yield signal weak returns